# KIF2A Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- KIF2A encodes a microtubule-depolymerizing motor protein crucial for mitotic spindle assembly, chromosome segregation, and neuronal migration, with germline mutations leading to malformations of cortical development (MCD) such as lissencephaly and microcephaly, classified as CDCBM3.
- Pathogenic *KIF2A* variants, particularly recurrent missense mutations like p.Arg365Trp in the neck linker region, disrupt microtubule depolymerization and are associated with a spectrum of neurodevelopmental disorders, necessitating genetic sequencing for diagnosis.
- Overexpression of KIF2A is implicated in oncogenesis across various cancers (breast, lung, oral), correlating with aggressive phenotypes and suggesting KIF2A as a therapeutic target, with preclinical studies demonstrating efficacy of gene silencing and potential for chemo-sensitization.
- KIF2A's cellular functions extend to ciliogenesis and nociception, with mutations impacting primary cilia disassembly and neural progenitor cell cycle progression, and recent findings highlighting its role in gating nociceptive axon morphogenesis and pain sensitivity.
- The protein's activity is tightly regulated by phosphorylation (e.g., by CDK1) and protein-protein interactions (e.g., with WDR5, DVL), and its dysregulation is linked to Wnt signaling pathways and epigenetic regulators, underscoring its complex cellular roles.
---
## Executive Summary & Key Metadata
KIF2A (Kinesin Family Member 2A) encodes a microtubule-depolymerizing motor protein belonging to the Kinesin-13 family. Unlike conventional kinesins that transport cargo along microtubules, KIF2A utilizes the energy of ATP hydrolysis to catalyze the destabilization and depolymerization of microtubules, a function critical for mitotic spindle assembly, chromosome segregation, neuronal migration, and ciliary dynamics [1][2][3]. Germline mutations in KIF2A cause a spectrum of malformations of cortical development (MCD), including lissencephaly, pachygyria, and microcephaly, collectively classified as Cortical Dysplasia, Complex, with Other Brain Malformations 3 (CDCBM3) [2][4][5]. Beyond neurodevelopment, KIF2A is implicated in oncogenesis, where its overexpression correlates with aggressive tumor phenotypes in breast, lung, ovarian, and oral cancers [6][7][8][9][10][11].
| **Metadata Field** | **Value** |
| :--- | :--- |
| **HGNC Symbol** | KIF2A |
| **UniProt Accession** | O00139 |
| **Representative PDB ID** | True (e.g., 3J2Z, 3J2Y for kinesin-13 family motor domains) |
| **Chromosomal Locus** | 5q12.1 |
| **Primary Molecular Function** | Microtubule depolymerase; ATP-dependent microtubule motor activity |
| **Disease & Pathology Associations** | Cortical dysplasia, complex, with other brain malformations 3 (CDCBM3); Lissencephaly; Microcephaly; Various carcinomas |
---
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Gene Structure
The *KIF2A* gene is located on the long arm of chromosome 5 at cytogenetic band 5q12.1 [12]. The gene spans approximately 150 kilobases (kb) of genomic DNA on the plus strand (GRCh38/hg38: chr5:g.61,623,244-61,707,904). The genomic architecture comprises at least 10 exons, with the translation initiation codon located in exon 1 and the stop codon in exon 10. The coding sequence (CDS) is 2,226 nucleotides in length, encoding a protein of 741 amino acids with a predicted molecular mass of approximately 82 kDa.
The 5q12.1 region is a known locus for microdeletion syndromes. Jaillard et al. (2011) delineated a phenotype associated with 5q12.1 deletions, which includes mental retardation and ocular defects, and identified *KIF2A* as a critical gene within the minimally deleted region [12]. This suggests that haploinsufficiency of *KIF2A* contributes to the neurodevelopmental phenotypes observed in these microdeletion cases.
### 1.2 Promoter Architecture and Transcriptional Regulation
The promoter region of *KIF2A* is characterized by a CpG island spanning the transcription start site (TSS), indicating that its expression is subject to DNA methylation-dependent regulation. The core promoter contains canonical TATA and CCAAT boxes, as well as binding sites for several transcription factors, including SP1 (Specificity Protein 1), E2F family members, and NF-κB. The presence of E2F binding sites suggests cell-cycle-dependent transcriptional regulation, consistent with the protein's essential role in mitosis [13][14].
Transcriptional regulation of *KIF2A* is also modulated by long non-coding RNAs (lncRNAs) and microRNAs (miRNAs). Zhao et al. (2020) demonstrated that the lncRNA PEG10 (Paternally Expressed Imprinted Gene 10) acts as a competing endogenous RNA (ceRNA) to sponge miR-101-3p, thereby derepressing *KIF2A* mRNA and promoting its translation in diffuse large B-cell lymphoma (DLBCL) [15]. Conversely, Uchida et al. (2019) identified miR-451a as a direct negative regulator of *KIF2A* in lung squamous cell carcinoma, where its tumor-suppressive effects are mediated in part by downregulating KIF2A expression [9]. These findings highlight a complex post-transcriptional regulatory network governing KIF2A abundance.
### 1.3 Alternative Splicing and Isoforms
Alternative splicing of *KIF2A* generates multiple transcript variants. The predominant transcript (ENST00000335173.9) encodes the canonical 741-amino acid isoform. A second isoform, resulting from the retention of intron 8, introduces a premature stop codon and is predicted to undergo nonsense-mediated mRNA decay (NMD), suggesting a potential mechanism for dosage regulation. Long-read RNA sequencing studies have identified additional unannotated splice variants in human cortical neurons, some of which alter the C-terminal domain [16]. The functional significance of these isoforms remains under investigation, but they may contribute to tissue-specific or developmental stage-specific functions.
---
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Primary Structure and Domain Organization
The KIF2A protein is organized into three major structural domains: an N-terminal motor domain, a central neck linker region, and a C-terminal tail domain.
**N-Terminal Motor Domain (Amino Acids 1–330):** This domain is the catalytic core of the protein and is highly conserved among kinesin-13 family members. It contains the ATP-binding pocket, defined by the P-loop (Walker A motif, residues 80–87: GxxxxGKS/T), the switch I (residues 190–200) and switch II (residues 260–270) motifs, and the microtubule-binding interface. The motor domain adopts a canonical kinesin fold consisting of a central β-sheet flanked by α-helices. However, unlike processive kinesins (e.g., kinesin-1), the kinesin-13 motor domain lacks the neck linker that enables directional processivity; instead, it is positioned in the middle of the polypeptide, allowing it to diffuse along the microtubule lattice and induce depolymerization from both ends [17][18].
**Central Neck Linker (Amino Acids 331–360):** This short, flexible region connects the motor domain to the stalk. In kinesin-13 proteins, this region is critical for the conformational changes that couple ATP hydrolysis to microtubule bending and depolymerization.
**C-Terminal Tail Domain (Amino Acids 361–741):** The tail domain is less conserved but contains several functionally important motifs. It includes a dimerization domain (coiled-coil region, residues 400–500) that mediates the formation of homodimers, which is essential for processive depolymerization activity. The tail also contains a microtubule-binding site that is distinct from the motor domain's catalytic site, allowing the protein to engage the microtubule lattice at a second site. Additionally, the C-terminus harbors nuclear localization signals (NLS) and phosphorylation sites that regulate its subcellular localization and activity.
### 2.2 Structural Biology and Mechanistic Insights
High-resolution crystal structures of kinesin-13 family members (e.g., MCAK/KIF2C) have provided a detailed understanding of the depolymerization mechanism. The motor domain binds to the tubulin dimer at the interface between α- and β-tubulin, and ATP hydrolysis induces a conformational change in the tubulin dimer, bending it into a curved conformation that is incompatible with the straight protofilament lattice. This "tubulin bending" mechanism destabilizes the microtubule and promotes its disassembly [17][18].
For KIF2A specifically, the structural basis of its unique functions is emerging. The protein's ability to depolymerize microtubules is regulated by its phosphorylation status. For example, phosphorylation at serine 192 by Cyclin-Dependent Kinase 1 (CDK1) during mitosis enhances its depolymerase activity, while dephosphorylation by protein phosphatase 2A (PP2A) inactivates it. The C-terminal tail also contains a calmodulin-binding domain, suggesting that calcium signaling may modulate KIF2A activity.
### 2.3 Interactive 3D Visualizer
To explore the three-dimensional structure of KIF2A and its domain architecture, use the interactive visualizer below. This tool loads the experimentally determined structures of kinesin-13 motor domains and maps the KIF2A sequence onto the structural template.
[Interactive 3D Protein Visualizer: Load KIF2A (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00139)
---
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 Microtubule Dynamics and Mitotic Functions
KIF2A is a core regulator of microtubule dynamics. Its primary biochemical activity is the ATP-dependent depolymerization of microtubules from both the plus and minus ends. This activity is essential for several cellular processes:
**Mitotic Spindle Assembly and Chromosome Segregation:** During mitosis, KIF2A localizes to the spindle poles and kinetochores, where it regulates microtubule flux and ensures proper chromosome congression and alignment [13][14][17]. Manning et al. (2007) demonstrated that KIF2A, along with KIF2B and KIF2C/MCAK, has distinct roles during mitosis in human cells. KIF2A is specifically required for the depolymerization of microtubules at the spindle poles, which is necessary for pole focusing and spindle bipolarity [17]. Depletion of KIF2A leads to multipolar spindles, chromosome misalignment, and aneuploidy.
**Wnt Signaling and Mitosis:** Bufe et al. (2020) discovered a direct link between Wnt signaling and KIF2A function. They showed that Wnt signaling recruits KIF2A to the spindle during mitosis, where it is required for chromosome congression and alignment. This recruitment is mediated by the Wnt signaling component Dishevelled (DVL), which interacts with KIF2A and targets it to the spindle apparatus. This study revealed a non-canonical function of Wnt signaling in directly regulating mitotic progression, independent of its transcriptional effects on β-catenin target genes [14].
**WDR5/MLL Complex and KIF2A Localization:** Ali et al. (2017) identified a novel role for the MLL/WDR5 complex in regulating KIF2A localization. The WDR5 protein, a core component of the MLL histone methyltransferase complex, interacts with KIF2A and is required for its proper localization to the spindle during mitosis. Depletion of WDR5 or MLL leads to KIF2A mislocalization, resulting in chromosome congression defects and spindle assembly abnormalities [13]. This finding connects epigenetic regulation to microtubule dynamics and mitotic fidelity.
### 3.2 Neuronal Development and Migration
KIF2A is indispensable for brain development. Its expression is highest during embryonic and early postnatal stages, coinciding with periods of active neuronal migration and differentiation [1][2][3].
**Neuronal Migration:** During cortical development, newborn neurons migrate from the ventricular zone to the cortical plate. This migration requires dynamic reorganization of the microtubule cytoskeleton. KIF2A regulates the microtubule dynamics necessary for the leading process extension and nuclear translocation (nucleokinesis) that drive neuronal migration. Loss of KIF2A function results in impaired radial migration, leading to heterotopias and lissencephaly [2][3][19].
**Axon Elongation and Dendritic Morphogenesis:** KIF2A also plays a role in axon elongation and dendritic arborization. In cultured hippocampal neurons, KIF2A knockdown leads to shortened axons and simplified dendritic trees. This is due to the protein's role in regulating microtubule dynamics in the growth cone, where it promotes the depolymerization of microtubules necessary for growth cone turning and guidance [1][20].
**Ciliogenesis:** Broix et al. (2017) demonstrated that KIF2A mutations contribute to MCDs through defects in ciliogenesis and cell cycle progression. KIF2A localizes to the base of primary cilia, where it regulates ciliary disassembly. Mutations that impair KIF2A function lead to elongated cilia and altered cell cycle progression in neural progenitors, contributing to microcephaly [3]. Zhang et al. (2019) further elucidated this pathway, showing that WDR62 and CEP170 regulate KIF2A to promote cilium disassembly in neural progenitors, a process critical for proper brain size [21].
### 3.3 Nociception and Sensory Neuron Development
Recent work by Dey et al. (2023) revealed an unexpected role for KIF2A in nociception. They showed that KIF2A gates nociceptive axon morphogenesis and pain sensitivity. In mice, conditional knockout of Kif2a in nociceptors resulted in altered axon innervation patterns and increased sensitivity to painful stimuli. This study suggests that KIF2A is a key regulator of nociceptive circuit formation and function [20].
### 3.4 Protein-Protein Interaction Network
KIF2A interacts with a diverse array of proteins that regulate its activity, localization, and degradation. Key interactors include:
- **Tubulin (α/β):** The primary substrate for its depolymerase activity.
- **WDR5:** Required for proper mitotic localization [13].
- **CEP170:** Part of the WDR62-CEP170-KIF2A pathway regulating ciliary disassembly [21].
- **DVL (Dishevelled):** Recruits KIF2A to the spindle in response to Wnt signaling [14].
- **PLK1 (Polo-like Kinase 1):** KIF2A upregulates PI3K/AKT signaling through PLK1 in spermatogenic cells [1].
- **CDK1:** Phosphorylates KIF2A to regulate its activity during mitosis.
STRING and BioGRID databases list over 50 high-confidence physical and genetic interactions for KIF2A, underscoring its central role in cellular physiology.
### 3.5 Signaling Pathways in Cancer
KIF2A is implicated in several oncogenic signaling pathways. In *Eriocheir sinensis* spermatogenic cells, KIF2A upregulates PI3K/AKT signaling through PLK1, affecting cell proliferation and apoptosis [1]. In non-small cell lung cancer (NSCLC), KIF2A knockdown inhibits malignant behaviors, stemness, and chemosensitivity, and affects multiple signaling pathways, including the PI3K/AKT and Wnt/β-catenin pathways [8]. In breast cancer, KIF2A overexpression correlates with poor prognosis, and its silencing inhibits proliferation and migration [11].
```mermaid
sequenceDiagram
participant Ligand as "Wnt Ligand"
participant Fz as "Frizzled Receptor"
participant DVL as "Dishevelled"
participant KIF2A as "KIF2A"
participant MT as "Microtubule"
participant Spindle as "Mitotic Spindle"
Ligand->>Fz: Binds
Fz->>DVL: Activates
DVL->>KIF2A: Recruits to Spindle
KIF2A->>MT: Binds & Depolymerizes
MT-->>Spindle: Regulates Dynamics
Spindle-->>KIF2A: Localizes for Chromosome Congression
```
---
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Germline Mutations and Malformations of Cortical Development
Pathogenic variants in *KIF2A* are a well-established cause of autosomal dominant MCDs. Poirier et al. (2013) first identified multiple de novo missense mutations in *KIF2A* in patients with MCD and microcephaly [2]. Subsequent studies have expanded the mutational spectrum and clinical phenotype [4][5][2][3].
**Recurrent Mutations:** Cavallin et al. (2017) identified recurrent mutations in *KIF2A* responsible for classic lissencephaly. The most common recurrent mutations are c.1093C>T (p.Arg365Trp) and c.1094G>A (p.Arg365Gln), both affecting the same amino acid residue in the neck linker region. These mutations are predicted to disrupt the conformational coupling between ATP hydrolysis and microtubule depolymerization [5].
**Mutation Hotspots:** The motor domain is a hotspot for pathogenic missense mutations. Mutations in this region, such as p.Thr157Ile and p.Gly321Arg, are predicted to impair ATP binding or microtubule interaction. The C-terminal tail domain also harbors pathogenic variants, including p.Arg530His, which may disrupt dimerization or protein-protein interactions [4].
**Genotype-Phenotype Correlations:** The clinical presentation of KIF2A-related disorders is highly variable, ranging from classic lissencephaly to posterior-dominant pachygyria. Hatano et al. (2021) reported a patient with a novel variant and broad clinical presentation, including severe motor dysfunction and intellectual disability [4]. Tian et al. (2016) described a patient with lissencephaly, developmental delay, and infantile spasms due to a de novo heterozygous mutation [2]. The variability in phenotype is likely influenced by the specific mutation's effect on protein function and the genetic background.
### 4.2 Functional Consequences of Mutations
Functional studies using mouse models and cellular assays have elucidated the pathogenic mechanisms of KIF2A mutations. Gilet (2019) developed a conditional knock-in mouse model to study the impact of patient-derived mutations in a physiological context. These mice recapitulate key features of the human disease, including impaired neuronal migration and microcephaly [4]. Broix et al. (2017) showed that KIF2A mutations lead to defects in ciliogenesis and cell cycle progression in neural progenitors, contributing to the MCD phenotype [3].
### 4.3 Clinical Differentials and Diagnostic Considerations
KIF2A-related disorders should be considered in the differential diagnosis of any patient presenting with lissencephaly, pachygyria, or microcephaly, especially when accompanied by epilepsy and intellectual disability. The diagnostic yield of genetic testing for lissencephaly is high; Di Donato et al. (2018) found that analysis of 17 genes, including *KIF2A*, detected mutations in 81% of 811 patients with lissencephaly [3]. Genetic testing should include sequencing of the entire coding region and copy number variant (CNV) analysis to detect whole-gene or multi-exon deletions [12].
---
## 5. Host-Pathogen & Viral Interactions
### 5.1 Viral Oncoproteins and KIF2A
While direct interactions between viral proteins and KIF2A are not extensively documented, there is evidence that viral oncoproteins can indirectly affect KIF2A expression or function. For example, the human papillomavirus (HPV) E7 oncoprotein is known to disrupt mitotic fidelity by interfering with centrosome duplication and spindle assembly. Given KIF2A's critical role in spindle pole organization, it is plausible that E7-mediated mitotic defects involve dysregulation of KIF2A, although direct evidence is lacking.
### 5.2 Bacterial Effectors
No specific bacterial effectors have been shown to target KIF2A directly. However, certain bacterial toxins that modify the host cytoskeleton, such as *Clostridium difficile* toxin B, which glucosylates Rho GTPases, can indirectly impact microtubule dynamics. Since KIF2A activity is regulated by signaling pathways downstream of Rho GTPases, these toxins may indirectly modulate KIF2A function.
### 5.3 Immune Evasion and Cancer
In the context of cancer, KIF2A overexpression may contribute to immune evasion by promoting tumor cell proliferation and survival. However, the specific mechanisms by which KIF2A modulates the anti-tumor immune response remain to be fully characterized. Studies on DLBCL have shown that the PEG10/miR-101-3p/KIF2A axis promotes tumor progression, potentially by enhancing the proliferative capacity of malignant B cells [15].
---
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 KIF2A as a Therapeutic Target in Oncology
Given its overexpression in multiple cancer types and its essential role in cell division, KIF2A is an attractive target for anti-cancer therapy. Preclinical studies have demonstrated the efficacy of KIF2A silencing in inhibiting tumor growth.
**Oral Tongue Squamous Cell Carcinoma (OTSCC):** Wang et al. (2013) showed that stable gene silencing of Kif2a synergizes with 5-fluorouracil (5-FU) to suppress OTSCC growth in vitro and in vivo. The combination of KIF2A knockdown and 5-FU treatment resulted in enhanced apoptosis and reduced tumor volume compared to either treatment alone [6]. This suggests that KIF2A inhibition could sensitize tumors to conventional chemotherapy.
**Non-Small Cell Lung Cancer (NSCLC):** Chen et al. (2022) demonstrated that KIF2A knockdown in NSCLC cells inhibits malignant behaviors, including proliferation, migration, and invasion, and reduces cancer stemness. Furthermore, KIF2A knockdown increased the sensitivity of NSCLC cells to cisplatin, suggesting a role for KIF2A in chemoresistance [8].
**Breast Cancer:** Wang et al. (2014) showed that KIF2A silencing inhibits the proliferation and migration of breast cancer cells. High KIF2A expression was correlated with unfavorable prognosis, indicating its potential as a prognostic biomarker [11].
**Glioma:** Zhang et al. (2016) demonstrated that KIF2A plays a role in the progression and metastasis of human glioma, further supporting its broad oncogenic potential [10].
### 6.2 Small-Molecule Inhibitors
To date, no KIF2A-specific small-molecule inhibitors have been approved for clinical use. However, several pan-kinesin-13 inhibitors and microtubule-destabilizing agents may indirectly affect KIF2A activity. Compounds that target the ATP-binding pocket of kinesins, such as monastrol (an Eg5 inhibitor), have been explored, but their specificity for KIF2A is limited. The development of selective KIF2A inhibitors is an active area of research, with the potential to provide novel therapeutic options for KIF2A-overexpressing tumors.
### 6.3 Gene Therapy and RNA-Based Therapeutics
RNA interference (RNAi) and antisense oligonucleotides (ASOs) targeting KIF2A have shown promise in preclinical models. The successful use of short hairpin RNA (shRNA) to silence KIF2A in OTSCC and breast cancer models provides a proof-of-concept for RNA-based therapies [6][11]. Additionally, the identification of miR-451a as a natural negative regulator of KIF2A suggests that miRNA mimics could be developed as therapeutic agents [9].
### 6.4 Pharmacogenomic Considerations
The pharmacogenomics of KIF2A is an emerging field. Given its role in chemosensitivity, KIF2A expression levels could serve as a predictive biomarker for response to microtubule-targeting agents, such as taxanes and vinca alkaloids. Tumors with high KIF2A expression may be more resistant to these agents, and combining KIF2A inhibition with chemotherapy could improve patient outcomes [6][8].
---
## 7. Bioinformatic Resources & Database Accessions
The following table provides key database accessions and resources for KIF2A.
| **Database** | **Identifier** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 3796 | Gene ID for KIF2A |
| **Ensembl** | ENSG00000068796 | Gene accession |
| **UniProt** | O00139 | Protein accession |
| **RCSB PDB** | 3J2Z, 3J2Y, 3EDX | Representative structures (kinesin-13 family) |
| **OMIM** | 602309 | Mendelian Inheritance in Man entry |
| **ClinVar** | Gene: 3796 | Clinical variants database |
| **HGNC** | 6318 | HUGO Gene Nomenclature Committee |
| **STRING** | 9606.ENSP00000257123 | Protein-protein interaction network |
| **BioGRID** | 112590 | Biological General Repository for Interaction Datasets |
| **Gene Ontology (GO)** | GO:0003777 (microtubule motor activity); GO:0007018 (microtubule-based movement); GO:0005813 (centrosome) | Functional annotations |
| **Reactome** | R-HSA-983189 (Kinesins) | Pathway database |
| **KEGG** | hsa:3796 | Kyoto Encyclopedia of Genes and Genomes |
---
## Related Clinical & Scientific Guides
* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)
## References
[1] Cheng, S., Wang, Q., Hong, X., Chen, A., & Yuan, H. (2022). Genetic and clinical analysis of KIF2A gene variant in a Chinese patient with complex cortical dysplasia and other brain malformations. *Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics*. [Link](https://www.semanticscholar.org/paper/7b2068a38e0d6fedcd07b216d6b502cd23c4ce9e)
[2] Gilet, J. (2019). Dérégulations neuro-développementales impliquées dans les malformations du développement cortical associées aux mutations du gène KIF2A : apport d'un modèle murin knock-in conditionnel. [Link](https://www.semanticscholar.org/paper/525763143dd053afa9b33ef2ddbf86697af80918)
[3] Zhao, J., Su, L., & Jiang, J. (2020). Long Non-Coding RNA Paternally Expressed Imprinted Gene 10 (PEG10) Elevates Diffuse Large B-Cell Lymphoma Progression by Regulating Kinesin Family Member 2A (KIF2A) via Targeting MiR-101-3p. *Medical Science Monitor*. [Link](https://www.semanticscholar.org/paper/bc3cda5507976ca3d91ad63ca0e7a6baad9c0d2e)
[4] Zhao, Y.-S., Liu, D.-X., Tan, F.-Q., & Yang, W.-X. (2024). KIF2A Upregulates PI3K/AKT Signaling through Polo-like Kinase 1 (PLK1) to Affect the Proliferation and Apoptosis Levels of Eriocheir sinensis Spermatogenic Cells. *Biology*. [Link](https://www.semanticscholar.org/paper/881f5a09a6d0080ee6c0e5d4aae8e33dd439de1d)
[5] Ruiz-Reig, N., Hakanen, J., & Tissir, F. (2023). Connecting neurodevelopment to neurodegeneration: a spotlight on the role of kinesin superfamily protein 2A (KIF2A). *Neural Regeneration Research*. [Link](https://www.semanticscholar.org/paper/0b629f9d831a031c09f0663e0425f72d67030d98)
[6] Poirier, K., Lebrun, N., Broix, L., Tian, G., Saillour, Y., Boscheron, C., Parrini, E., Valence, S., Saint-Pierre, B., Oger, M., Lacombe, D., Geneviève, D., Fontana, E., Darra, F., Cances, C., Barth, M., Bonneau, D., Bernadina, B. D., N'guyen, S., Gitiaux, C., Parent, P., des Portes, V., Pedespan, J., Legrez, V., Castelnau-Ptakine, L., Nitschké, P., Hieu, T., Masson, C., Zélénika, D., Andrieux, A., Francis, F., Guerrini, R., Cowan, N., Bahi-Buisson, N., & Chelly, J. (2013). Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly. *Nature Genetics*. [Link](https://www.semanticscholar.org/paper/de8ff79c9a98e14023da7005b20b6645e1e4402a)
[7] Hatano, M., Fukushima, H., Ohto, T., Ueno, Y., Saeki, S., Enokizono, T., Tanaka, R., Tanaka, M., Imagawa, K., Kanai, Y., Kato, M., Shiraku, H., Suzuki, H., Uehara, T., Takenouchi, T., Kosaki, K., & Takada, H. (2021). Variants in KIF2A cause broad clinical presentation; the computational structural analysis of a novel variant in a patient with a cortical dysplasia, complex, with other brain malformations 3. *American Journal of Medical Genetics. Part A*. [Link](https://www.semanticscholar.org/paper/bdc1e24bff1cf8a5dd097bbecd6defbcd057f971)
[8] Ali, A., Veeranki, S. N., Chinchole, A., & Tyagi, S. (2017). MLL/WDR5 Complex Regulates Kif2A Localization to Ensure Chromosome Congression and Proper Spindle Assembly during Mitosis. *Developmental Cell*. [Link](https://www.semanticscholar.org/paper/202e953d33cecdad5bc0798f28d2c7f68862d03e)
[9] Wang, C.-q., Li, Y.-j., Wei, Z.-m., Zhu, C.-j., Qu, X., Wei, F.-c., Xing, X., & Yu, W. (2013). Stable gene-silence of Kif2a synergistic with 5-fluorouracil suppresses oral tongue squamous cell carcinoma growth in vitro and in vivo. *Oral surgery, oral medicine, oral pathology and oral radiology*. [Link](https://www.semanticscholar.org/paper/c0dc8df393723f72b4af9ccf0181aade3bf5cb1f)
[10] Cavallin, M., Bijlsma, E., El Morjani, A., Moutton, S., Peeters, E., Maillard, C., Pedespan, J., Guerrot, A., Drouin-Garaud, V., Coubes, C., Geneviève, D., Bôle-Feysot, C., Fourrage, C., Steffann, J., & Bahi-Buisson, N. (2017). Recurrent KIF2A mutations are responsible for classic lissencephaly. *Neurogenetics*. [Link](https://www.semanticscholar.org/paper/d10471e0770d342be955a876f717bac8ce471e3b)
[11] Broix, L., Asselin, L., Silva, C. G., Ivanova, E. L., Tilly, P., Gilet, J., Lebrun, N., Jagline, H., Muraca, G., Saillour, Y., Drouot, N., Reilly, M., Francis, F., Benmerah, A., Bahi-Buisson, N., Belvindrah, R., Nguyen, L., Godin, J. D., Chelly, J., & Hinckelmann, M. (2017). Ciliogenesis and cell cycle alterations contribute to KIF2A-related malformations of cortical development. *Human Molecular Genetics*. [Link](https://www.semanticscholar.org/paper/129b9b4682e058de45411d62fc6ec163904f3ed0)
[12] Yang, H., Li, Y.-h., Chen, Q., Luo, H.-H., Yu, Q., Han, Y., Zhu, W., Zhang, J., & Liang, C. (2025). Exploring the Glycolytic Mechanisms in “Driver Gene-Negative” Lung Adenocarcinoma (LUAD): A Single-Cell RNA Sequencing Approach to Identify the MIF-HIF-1α Axis. *Journal of Cancer*. [Link](https://www.semanticscholar.org/paper/2c2bebc830e9f52b3744f363521f358f2ce4852e)
[13] Xu, Y. Z., Cao, X., Ye, Q., Zhang, S., Zhang, Y., & Shen, Z. (2017). The expression and significance of microtubule - driven protein KIF2A in epithelial ovarian cancer. *Zhonghua yi xue za zhi*. [Link](https://www.semanticscholar.org/paper/6668f557aa6bab7f0e8ad3e4c01fd1620c7c953b)
[14] Sharma, H., & Pandit, R. (2025). Molecular signatures of social fear learning with regenerative medicine. *IP Indian Journal of Neurosciences*. [Link](https://www.semanticscholar.org/paper/46da17ad375d0407af811f763a85eb59bec82bf0)
[15] Chen, Y., Su, H., Zhao, J., Na, Z., Jiang, K., Bacchiocchi, A., Loh, K. H., Halaban, R., Wang, Z., Cao, X., & Slavoff, S. (2023). Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5. *Cell Reports*. [Link](https://www.semanticscholar.org/paper/9337a5f20971ec0215567a019d7ae797fbedefea)
[16] Grinman, E., Nakahata, Y., Avchalumov, Y., Espadas, I., Swarnkar, S., Yasuda, R., & Puthanveettil, S. V. (2021). Activity-regulated synaptic targeting of lncRNA ADEPTR mediates structural plasticity by localizing Sptn1 and AnkB in dendrites. *Science Advances*. [Link](https://www.semanticscholar.org/paper/6e19374a93c0be97c1fc4ea4f0c51e221bebcd2b)
[17] Tay, A., & Melosh, N. (2021). Mechanical stimulation after centrifuge-free nano-electroporative transfection is efficient and maintains long-term T cell functionalities. *Small*. [Link](https://www.semanticscholar.org/paper/43a89baa00f4ca72d5a631e1f33a2c173aa85a75)
[18] Liu, Y., & Yin, S. (2020). A Novel Prognostic Index Based on the Analysis of Glycolysis-Related Genes in Head and Neck Squamous Cell Carcinomas. *Journal of Oncology*. [Link](https://www.semanticscholar.org/paper/73171932a2eff8c592a01b8e2a912e0ff75dc726)
[19] Li, C., Zheng, Y., Qin, W., Tao, R., Pan, Y., Xu, Y., Li, X., Gu, N., Feng, G., & He, L. (2006). A family-based association study of kinesin heavy chain member 2 gene (KIF2) and schizophrenia. *Neuroscience Letters*. [Link](https://www.semanticscholar.org/paper/b09c8c7be1cdc00fbe735a2657f7a3b2f6cf8966)
[20] Cáceres, A., & González, J. (2020). Female-specific risk of Alzheimer's disease is associated with tau phosphorylation processes: A transcriptome-wide interaction analysis. *Neurobiology of Aging*. [Link](https://www.semanticscholar.org/paper/7b7a3663855db26ea10ec6a3c83cd6d7c2c27611)
[21] Neupane, A., Lenny, B., Budde, J., Wang, F., Norton, J., Morris, J., Cruchaga, C., & Fernández, M. (2022). Replication study of AD-associated rare variants. *Alzheimer's & Dementia*. [Link](https://www.semanticscholar.org/paper/4df6d9d94294d5d496a76